Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07108036 · ClinicalTrials.gov registry record · Phase 2
A Study to Assess Anktiva in Patients With Long Covid-19.
A Phase 2 study, sponsored by ImmunityBio.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 20
- Enrollment target
NCT07108036: Recruiting Phase 2 study, sponsored by ImmunityBio.
NCT07108036 is a Phase 2 study that is actively recruiting participants, run by ImmunityBio. The registered enrollment target is 20 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (85% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07108036, a Phase 2 study, is actively recruiting participants, sponsored by ImmunityBio.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 20 participants
- Enrollment target
Study Summary
This study will test the safety and tolerability of Anktiva in patients with Long Covid. Eligible patients will receive up to 2 doses of Anktiva and have follow-up exams and tests.
Interventions
- DRUG N-803 (IL-15 Superagonist)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2025-11-14 |
| Est. Completion | 2026-10 |
| Phase | Phase 2 |
What NCT07108036 shows while recruiting
NCT07108036 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 20 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (85% lower).
The record links to 0 conditions, and to 1 intervention - of which N-803 (IL-15 Superagonist) is the first listed.
NCT07108036 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT07108036 about?
NCT07108036 is a clinical study titled "A Study to Assess Anktiva in Patients With Long Covid-19.". This study will test the safety and tolerability of Anktiva in patients with Long Covid. Eligible patients will receive up to 2 doses of Anktiva and have follow-up exams and tests.
What is the current status of trial NCT07108036?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 20 participants. The study started on 2025-11-14. Estimated completion is 2026-10.
What interventions are being tested in trial NCT07108036?
The interventions under investigation include: N-803 (IL-15 Superagonist) (DRUG).
Who is sponsoring clinical trial NCT07108036?
This trial is sponsored by ImmunityBio, which has 46 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT07108036's enrollment target sits among peer trials
20 1805th of 2000 higher than 107 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00573339 · 20 participants
Cardiac Magnetic Resonance Imaging (MRI) Normal Reference Control Group Testing
- NCT00692939 · 20 participants · Phase 1
Autologous Stem Cell Transplantation for Crohn's Disease
- NCT00967785 · 20 participants · Phase 1
A Phase I Study of Mozobil in the Treatment of Patients With WHIMS
- NCT01406691 · 20 participants · Phase 4
Light Flashes to Treat Delayed Sleep Phase Disorder (DSPD)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI